RU2016141405A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016141405A3 RU2016141405A3 RU2016141405A RU2016141405A RU2016141405A3 RU 2016141405 A3 RU2016141405 A3 RU 2016141405A3 RU 2016141405 A RU2016141405 A RU 2016141405A RU 2016141405 A RU2016141405 A RU 2016141405A RU 2016141405 A3 RU2016141405 A3 RU 2016141405A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163734 | 2014-04-07 | ||
| EP14163734.8 | 2014-04-07 | ||
| EP15153207.4 | 2015-01-30 | ||
| EP15153207 | 2015-01-30 | ||
| PCT/EP2015/056839 WO2015155042A1 (en) | 2014-04-07 | 2015-03-30 | (5,6-dihydro)pyrimido[4,5-e]indolizines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016141405A RU2016141405A (ru) | 2018-05-07 |
| RU2016141405A3 true RU2016141405A3 (cg-RX-API-DMAC7.html) | 2018-10-02 |
| RU2692479C2 RU2692479C2 (ru) | 2019-06-25 |
Family
ID=52774240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016141405A RU2692479C2 (ru) | 2014-04-07 | 2015-03-30 | (5,6-дигидро)пиримидо[4,5-е]индолизины |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | USRE50082E1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3129374B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6518690B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102432420B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106132963B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015243694B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016022342B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2944610C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3129374T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2716165T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE043108T2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX368767B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3129374T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3129374T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2692479C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015155042A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2944610C (en) * | 2014-04-07 | 2024-01-09 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indolizines |
| ES2966392T3 (es) | 2015-04-17 | 2024-04-22 | Crossfire Oncology Holding B V | Biomarcadores pronósticos para quimioterapia inhibidora de TTK |
| MX376974B (es) * | 2016-02-19 | 2025-03-07 | Phoenix Molecular Designs | Derivados de carboxamida útiles como inhibidores de rsk. |
| MX388576B (es) | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| CN106551938B (zh) * | 2016-11-26 | 2017-11-24 | 广东安诺药业股份有限公司 | 一种治疗非酒精性脂肪肝的药物及其应用 |
| EA202190196A1 (ru) | 2017-03-23 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| CA3129722A1 (en) | 2019-02-11 | 2020-08-20 | Phoenix Molecular Designs | Crystalline forms of an rsk inhibitor |
| MX2024007452A (es) * | 2021-12-15 | 2024-07-09 | Sillajen Inc | Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas. |
| US20250057844A1 (en) * | 2021-12-15 | 2025-02-20 | Sillajen, Inc. | Methods of treating neoplastic diseases |
| EP4447970A4 (en) * | 2021-12-15 | 2025-10-22 | Sillajen Inc | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF CANCER |
| EP4486350A4 (en) * | 2022-03-04 | 2026-01-21 | Sillajen Inc | PHARMACEUTICAL COMBINATIONS INTENDED FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0212760A (pt) * | 2001-09-19 | 2004-12-07 | Aventis Pharma Sa | Compostos quìmicos |
| BR122019010200B8 (pt) | 2003-05-22 | 2021-07-27 | Nerviano Medical Science S R L | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas |
| EP2118102B1 (en) | 2006-11-28 | 2013-06-12 | Nerviano Medical Sciences S.r.l. | Tricyclic indoles and (4,5-dihydro) indoles |
| EA020703B9 (ru) * | 2008-06-26 | 2015-12-30 | Ле Лаборатуар Сервье | Пиразолохиназолины |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| US8586598B2 (en) | 2009-04-29 | 2013-11-19 | Nerviano Medical Sciences S.R.L. | CDK inhibitor salts |
| ES2553114T3 (es) | 2009-07-29 | 2015-12-04 | Nerviano Medical Sciences S.R.L. | Sales de inhibidor de plk |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| JP2014503521A (ja) * | 2010-12-17 | 2014-02-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過増殖性障害の処置におけるｍｐｓ−１およびｔｋｋ阻害剤としての使用のための、イミダゾピラジン類 |
| EP2668190B1 (en) * | 2011-01-26 | 2016-08-17 | Nerviano Medical Sciences S.r.l. | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
| WO2014209978A1 (en) | 2013-06-24 | 2014-12-31 | Merck Patent Gmbh | Imidazole compounds as modulators of fshr and uses thereof |
| CA2944610C (en) * | 2014-04-07 | 2024-01-09 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indolizines |
-
2015
- 2015-03-30 CA CA2944610A patent/CA2944610C/en active Active
- 2015-03-30 BR BR112016022342-0A patent/BR112016022342B1/pt active IP Right Grant
- 2015-03-30 RU RU2016141405A patent/RU2692479C2/ru active
- 2015-03-30 US US17/579,990 patent/USRE50082E1/en active Active
- 2015-03-30 AU AU2015243694A patent/AU2015243694B2/en active Active
- 2015-03-30 CN CN201580017365.8A patent/CN106132963B/zh active Active
- 2015-03-30 ES ES15712912T patent/ES2716165T3/es active Active
- 2015-03-30 EP EP15712912.3A patent/EP3129374B1/en active Active
- 2015-03-30 PL PL15712912T patent/PL3129374T3/pl unknown
- 2015-03-30 MX MX2016012997A patent/MX368767B/es active IP Right Grant
- 2015-03-30 US US15/128,874 patent/US9856258B2/en not_active Ceased
- 2015-03-30 HU HUE15712912A patent/HUE043108T2/hu unknown
- 2015-03-30 JP JP2016560952A patent/JP6518690B2/ja active Active
- 2015-03-30 DK DK15712912.3T patent/DK3129374T3/en active
- 2015-03-30 WO PCT/EP2015/056839 patent/WO2015155042A1/en not_active Ceased
- 2015-03-30 KR KR1020167031029A patent/KR102432420B1/ko active Active
- 2015-03-30 US US16/728,900 patent/USRE48974E1/en active Active
- 2015-03-30 PT PT15712912T patent/PT3129374T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3129374A1 (en) | 2017-02-15 |
| MX368767B (es) | 2019-10-15 |
| EP3129374B1 (en) | 2018-12-19 |
| CN106132963B (zh) | 2019-08-06 |
| RU2016141405A (ru) | 2018-05-07 |
| JP6518690B2 (ja) | 2019-05-22 |
| USRE48974E1 (en) | 2022-03-15 |
| KR20170013866A (ko) | 2017-02-07 |
| USRE50082E1 (en) | 2024-08-20 |
| HUE043108T2 (hu) | 2019-07-29 |
| MX2016012997A (es) | 2016-12-07 |
| RU2692479C2 (ru) | 2019-06-25 |
| BR112016022342A2 (pt) | 2017-08-15 |
| ES2716165T3 (es) | 2019-06-10 |
| CN106132963A (zh) | 2016-11-16 |
| BR112016022342B1 (pt) | 2022-10-04 |
| BR112016022342A8 (pt) | 2021-07-20 |
| DK3129374T3 (en) | 2019-04-08 |
| US20170096432A1 (en) | 2017-04-06 |
| WO2015155042A1 (en) | 2015-10-15 |
| JP2017510595A (ja) | 2017-04-13 |
| CA2944610A1 (en) | 2015-10-15 |
| AU2015243694A1 (en) | 2016-11-03 |
| CA2944610C (en) | 2024-01-09 |
| AU2015243694B2 (en) | 2019-01-17 |
| PL3129374T3 (pl) | 2019-07-31 |
| US9856258B2 (en) | 2018-01-02 |
| KR102432420B1 (ko) | 2022-08-17 |
| PT3129374T (pt) | 2019-03-25 |